The American Institute for Medical and Biological Engineering (AIMBE) is a non-profit organization headquartered in Washington, D.C., representing the most accomplished individuals in the fields of medical and biological engineering

AIMBE has launched a new lecture series on the campuses of colleges and universities across the country to discuss “The Science of Failed Public Policy – Why Congress Doesn’t Fund Medical Innovation,” hosted by AIMBE Executive Director Milan Yager.

The American Institute for Medical and Biological Engineering (AIMBE) is a non-profit organization headquartered in Washington, D.C., representing the most accomplished individuals in the fields of medical and biological engineering

AIMBE has launched a new lecture series on the campuses of colleges and universities across the country to discuss “The Science of Failed Public Policy – Why Congress Doesn’t Fund Medical Innovation,” hosted by AIMBE Executive Director Milan Yager.

AIMBE College of Fellows Class of 2008
For pioneering contributions to cell culture engineering and molecular methods for diagnosis and therapy of disease at the genetic level.

Image: A new study explains how increased calcium levels trigger the production of melanin, causing a mole to form (Photo courtesy of ETH Zurich).

A new study describes how a mole-like synthetic implant recognizes the elevated levels of calcium in the blood associated with incipient prostate, lung, colon, and breast cancer tumors.

Developed by researchers at ETH Zurich (Switzerland) and the University of Basel (Switzerland), the so-called early warning system is comprised of an encapsulated gene network integrated into human body cells implanted under the skin, where it constantly monitors blood calcium levels. When calcium levels exceed a pre-determined threshold, a synthetic signaling cascade expresses transgenic tyrosinase, which triggers the production of melanin in the genetically modified cells. The skin then forms a brown mole that is visible to the naked eye.

The researchers validated the design in wild-type mice inoculated with hypercalcemic breast and colon adenocarcinoma cells. The mice, which were implanted with the subcutaneous encapsulated engineered cells, all developed tattoos, whereas no tattoos were seen in animals inoculated with normo-calcemic tumor cells. The study also confirmed that the synthetic biomedical mole could not only be detected with the naked eye, but could also optically quantified. All animals remained asymptomatic throughout the 38-day experimental period. The study was published on April 18, 2018, in Science Translational Medicine… Continue reading.

Researchers have developed a novel strategy that could usher in a new era of pain management and combat the persistent problem of painkiller addiction.

A new study highlighted a bioengineering-based method that involves engineering cells that can target pain receptors and then tie those cells to an aroma-based triggering mechanism. “Our proof-of-principle findings indicate that therapies based on engineered cells can achieve robust, tunable and on-demand analgesia for the long-term management of chronic pain,” the study authors wrote.

The strategy works in a number of steps. First, researchers created “microencapsulated human designer cells” that produce Huwentoxin-IV, a potent analgesic peptide that selectively shuts down a pain-triggering sodium channel called Nav1.7. Next, they rewired an olfactory receptor, OR1A1, so that it induced the expression of a variant of Huwentoxin-IV. The researchers chose an olfactory receptor that is responsive to R-carvone, a chemical that smells like spearmint.

Thus, the researchers created a mechanism in which the smell of spearmint leads to the production of Huwentoxin-IV, which in turn eliminates pain. The so-called “AromaCells” were tested in mouse models, and the results suggested the mice achieved significant and lasting pain relief with exposed to spearmint.

Martin Fussenegger, PhD, the lead author and a professor in the Department of Biosystems Science and Bioengineering at ETH Zurich (Swiss Federal Institute of Technology, Zurich), said the system circumvents one of the key problems associated with pain management… Continue reading.

Researchers led by ETH Zurich professor Martin Fussenegger have constructed the first gene network that can be controlled by our thoughts. The inspiration for this development was a game that picks up brainwaves in order to guide a ball through an obstacle course.

It sounds like something from the scene in Star Wars where Master Yoda instructs the young Luke Skywalker to use the force to release his stricken X-Wing from the swamp: Marc Folcher and other researchers from the group led by Martin Fussenegger, Professor of Biotechnology and Bioengineering at the Department of Biosystems (D-BSSE) in Basel, have developed a novel gene regulation method that enables thought-specific brainwaves to control the conversion of genes into proteins – called gene expression in technical terms.
"For the first time, we have been able to tap into human brainwaves, transfer them wirelessly to a gene network and regulate the expression of a gene depending on the type of thought. Being able to control gene expression via the power of thought is a dream that we’ve been chasing for over a decade," says Fussenegger.

What is AIMBE?

The American Institute for Medical and Biological Engineering (AIMBE) is the authoritative voice and advocate for the value of medical and biological engineering to society. It is an organization of leaders in medical and biological engineering, consisting of academic, industrial, professional society councils and elected fellows.

AIMBE Fellowbook

Fellowbook Profiles are micro-blogs for each of our Fellows. New stories are added to showcase their accomplishments.